Skip to main content
Premium Trial:

Request an Annual Quote

NIH Seeks License, Collaborators for HPV-related Cervical Cancer miRNAs

NEW YORK (GenomeWeb News) – The National Institutes of Health has made available for licensing miRNA technology that could be used to develop a diagnostic or a therapeutic for cervical cancer tumors related to cases of human papillomavirus.
The NIH also said it is seeking statements of capability or interest from parties who may wish to engage in collaborative research to develop, evaluate, or commercialize the p53 specific miR-34, which it said is downregulated in HPV-infected primary keratinocytes. The miR-34 has been shown to arrest the cell cycle at a certain phase in tumor development and to promote apoptosis.
Information about the miRNA technology was published in 2007 in the July issue of Cancer Research and the Nov. 12 edition of Oncogene

The miRNA technology’s provisional application, number 60/983,368, was filed in October 2007, and its reference number is E-029-2008/0-US-01.

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.